Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 57

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 57
---
 the proceeds in investment grade interest bearing instruments or will hold the
proceeds in interest bearing or non-interest-bearing bank accounts.

<div align='center'>30

DETERMINATION OF THE OFFERING PRICE</div>

The offering price of the Units in the Primary
Offering has been determined arbitrarily by us. This price does not bear any relationship to our book value, earnings, or other established
criteria that would be evaluated for a company with an established public market. In determining the number of Units to be offered and
the offering price per unit, we took into consideration our cash on hand and the amount of money we would need to implement our business
plan. Accordingly, the offering price should not be considered an indication of the actual value of the securities. Unless and until
our Common Stock is listed on a national securities exchange or quoted on OTCQB or OTCQX, our Common Stock and Units comprised of common
stock may be sold only at the fixed price. Notwithstanding our belief that upon the effective date of this registration statement our
Common Stock will satisfy the admission requirements for the OTCQB and our intention to make application for quotation on the OTCQB Market,
we cannot assure you that our Common Stock will be quoted on the OTCQB tier.

<div align='center'>31

CAPITALIZATION</div>

The following table sets forth our cash and cash equivalents and
capitalization as of March 31, 2025:

| ● | on an actual basis; and                                                                                                                  |
| ● | On a pro forma basis                                                                                                                     
 to give effect to the sale by us of 1,562,500 Units at the fixed public offering price of $3.20 per Unit (assuming the sale of all       
 securities offered hereby and assuming no exercise of the IPO Warrants issued in connection with this Primary Offering), after deducting 
 estimated offering expenses payable by us as if the sale of the securities had occurred on March 31, 2025.                               |

You should read this information together with
our consolidated financial statements and related notes, as well as the information set forth under the headings “Use of Proceeds”
and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” appearing elsewhere
in this prospectus.

|                                                                                                                                          |     | As of March 31, 
 2025            |         |   |     |           |         |   |
|:-----------------------------------------------------------------------------------------------------------------------------------------|:----|:----------------|--------:|:--|:----|